Company Description
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.
In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 6, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 540 |
| CEO | John Evans |
Contact Details
Address: 238 Main Street Cambridge, Massachusetts 02142 United States | |
| Phone | 857 327 8775 |
| Website | beamtx.com |
Stock Details
| Ticker Symbol | BEAM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001745999 |
| CUSIP Number | 07373V105 |
| ISIN Number | US07373V1052 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John M. Evans M.B.A. | Chief Executive Officer and Director |
| Dr. Giuseppe Ciaramella Ph.D. | President |
| Sravan Kumar Emany | Chief Financial Officer |
| Dr. Christine P. Bellon J.D., Ph.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Amy Simon M.D. | Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder |
| Dr. David R. Liu Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Bethany J. Cavanagh M.B.A. | Senior Vice President of Finance, Treasurer and Principal Accounting Officer |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | 144 | Filing |
| Oct 15, 2026 | 144 | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |
| Aug 4, 2026 | 10-Q | Quarterly Report |
| Aug 4, 2026 | 8-K | Current Report |
| Jul 27, 2026 | 144 | Filing |
| Jun 30, 2026 | 144 | Filing |
| Jun 29, 2026 | 144 | Filing |
| Jun 8, 2026 | 8-K | Current Report |